Abstract
In this study, we demonstrate a novel mechanism by which down-regulation of transforming growth factor β type II receptor (TβRII) is mediated by a histone deacetylase (HDAC) in pancreatic ductal adenocarcinoma (PDAC) cells. Treatment of PDAC cell lines BxPC-3 and MIA PaCa-2 with a specific HDAC inhibitor, trichostatin A (TSA), strongly activates TβRII promoter activity and induces TβRII expression. The transcriptional activation of TβRII by TSA was correlated with a decrease in HDAC activity and an increase in acetylated histone H4 protein. Correspondingly, an increase in the association of TβRII promoter with acetylated histone H4 was detected in the TSA-treated cells as determined by a chromatin immunoprecipitation assay. We found that a specific Sp1 site (Sp1C, located at -102 bp relative to the transcription start site) adjacent to an inverted CCAAT box (-83 bp) is required for TSA-mediated activation of the TβRII promoter. Furthermore, we determined that HDAC1 complexed with Sp1 in PDAC cells and that TSA treatment interfered with this association. Diminished binding of HDAC1 to the -112 to -65 bp region of the TβRII promoter after TSA treatment was confirmed by a DNA affinity precipitation assay. This is the first study to demonstrate the requirement of a specific Sp1 site for TSA-mediated transcriptional activation of TβRII. This study further suggests that the specificity of this Sp1 site for HDAC-mediated repression of TβRII may involve the interaction of the Sp1-HDAC1 complex with components of the cognate transcriptional regulators that bind to the inverted CCAAT box.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2624-2630 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 63 |
| Issue number | 10 |
| State | Published - May 15 2003 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor β type II receptor expression in human pancreatic cancer cells. / Zhao, Shujie; Venkatasubbarao, Kolaparthi; Li, Senlin; Freeman, James W.
In: Cancer Research, Vol. 63, No. 10, 15.05.2003, p. 2624-2630.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor β type II receptor expression in human pancreatic cancer cells
AU - Zhao, Shujie
AU - Venkatasubbarao, Kolaparthi
AU - Li, Senlin
AU - Freeman, James W
PY - 2003/5/15
Y1 - 2003/5/15
N2 - In this study, we demonstrate a novel mechanism by which down-regulation of transforming growth factor β type II receptor (TβRII) is mediated by a histone deacetylase (HDAC) in pancreatic ductal adenocarcinoma (PDAC) cells. Treatment of PDAC cell lines BxPC-3 and MIA PaCa-2 with a specific HDAC inhibitor, trichostatin A (TSA), strongly activates TβRII promoter activity and induces TβRII expression. The transcriptional activation of TβRII by TSA was correlated with a decrease in HDAC activity and an increase in acetylated histone H4 protein. Correspondingly, an increase in the association of TβRII promoter with acetylated histone H4 was detected in the TSA-treated cells as determined by a chromatin immunoprecipitation assay. We found that a specific Sp1 site (Sp1C, located at -102 bp relative to the transcription start site) adjacent to an inverted CCAAT box (-83 bp) is required for TSA-mediated activation of the TβRII promoter. Furthermore, we determined that HDAC1 complexed with Sp1 in PDAC cells and that TSA treatment interfered with this association. Diminished binding of HDAC1 to the -112 to -65 bp region of the TβRII promoter after TSA treatment was confirmed by a DNA affinity precipitation assay. This is the first study to demonstrate the requirement of a specific Sp1 site for TSA-mediated transcriptional activation of TβRII. This study further suggests that the specificity of this Sp1 site for HDAC-mediated repression of TβRII may involve the interaction of the Sp1-HDAC1 complex with components of the cognate transcriptional regulators that bind to the inverted CCAAT box.
AB - In this study, we demonstrate a novel mechanism by which down-regulation of transforming growth factor β type II receptor (TβRII) is mediated by a histone deacetylase (HDAC) in pancreatic ductal adenocarcinoma (PDAC) cells. Treatment of PDAC cell lines BxPC-3 and MIA PaCa-2 with a specific HDAC inhibitor, trichostatin A (TSA), strongly activates TβRII promoter activity and induces TβRII expression. The transcriptional activation of TβRII by TSA was correlated with a decrease in HDAC activity and an increase in acetylated histone H4 protein. Correspondingly, an increase in the association of TβRII promoter with acetylated histone H4 was detected in the TSA-treated cells as determined by a chromatin immunoprecipitation assay. We found that a specific Sp1 site (Sp1C, located at -102 bp relative to the transcription start site) adjacent to an inverted CCAAT box (-83 bp) is required for TSA-mediated activation of the TβRII promoter. Furthermore, we determined that HDAC1 complexed with Sp1 in PDAC cells and that TSA treatment interfered with this association. Diminished binding of HDAC1 to the -112 to -65 bp region of the TβRII promoter after TSA treatment was confirmed by a DNA affinity precipitation assay. This is the first study to demonstrate the requirement of a specific Sp1 site for TSA-mediated transcriptional activation of TβRII. This study further suggests that the specificity of this Sp1 site for HDAC-mediated repression of TβRII may involve the interaction of the Sp1-HDAC1 complex with components of the cognate transcriptional regulators that bind to the inverted CCAAT box.
UR - http://www.scopus.com/inward/record.url?scp=0038519756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038519756&partnerID=8YFLogxK
M3 - Article
C2 - 12750289
AN - SCOPUS:0038519756
VL - 63
SP - 2624
EP - 2630
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 10
ER -